Immediate Impact
60 standout
Citing Papers
Strategic advancements in targeting the PI3K/AKT/mTOR pathway for Breast cancer therapy
2025 Standout
Pancreatic cancer
2025 Standout
Works of John Wu being referenced
Bgb-A425, an investigational anti-TIM-3 monoclonal antibody, in combination with tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: A phase I/II trial in progress.
2020
Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial
2019
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| John Wu | 98 | 136 | 32 | 62 | 26 | 277 | |
| Jebrane Bouaoud | 110 | 89 | 17 | 89 | 45 | 324 | |
| Chan Hee Park | 62 | 72 | 66 | 59 | 27 | 301 | |
| Dipti Thakkar | 101 | 90 | 40 | 61 | 21 | 316 | |
| Gabriela Capriotti | 101 | 39 | 30 | 38 | 25 | 301 | |
| Howard D. Wang | 99 | 96 | 48 | 55 | 21 | 328 | |
| Holyoke Ed | 134 | 164 | 49 | 45 | 23 | 305 | |
| Ibrahim Zakhary | 48 | 88 | 30 | 61 | 22 | 322 | |
| Andreas Mamilos | 80 | 52 | 10 | 76 | 32 | 264 | |
| Dongsheng Cao | 117 | 47 | 19 | 71 | 31 | 285 | |
| Jenna R. Stoehr | 54 | 82 | 10 | 30 | 29 | 295 |
All Works
Login with ORCID to disown or claim papers
Loading papers...